Skip to main content
Our story

About Us

Browse:

To deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.

Man on laptop smiling
Close up of microscope with slide

Our Values

Moderna people hold a deep sense of responsibility for each other, patients, the environment and our local communities. Our people live our Values every day.

 
Bold
Bold
Collaborative
Collaborative
Relentless
Relentless
Curious
Curious

We’re making biotech history

Messenger RNA is not new technology, but we are discovering new ways to use it to treat and prevent illnesses and diseases. Since our founding in 2010, we have worked to build the industry's leading mRNA technology platform. 

Scientist in the lab using technical instrument

Our big moments

Moderna incorporates
2010

Moderna incorporates

Moderna’s name combines the words "modified" and "RNA", which happens to contain the word "modern.” 

Operations started
2011

Operations started

Moderna begins research into the production of mRNA medicines. Stéphane Bancel joins as founding CEO.

First human dose of flu vaccine
2015

First human dose of flu vaccine

Moderna initiates first-in-human dose of an mRNA vaccine (mRNA-1440), an H10N8 flu vaccine candidate.

First human dose of multivalent vaccine
2017

First human dose of multivalent vaccine

Moderna initiates first-in-human dosing for mRNA-1653, a combination vaccine with the potential to protect against more than one disease – human metapneumovirus (hMPV virus) and parainfluenza virus.

First antibody encoded by mRNA
October 2019

First antibody encoded by mRNA

Moderna announces dosing of the first antibody encoded by mRNA in a clinical trial

UK Medicines and Healthcare products Regulatory Agency (MHRA)
October 2020

UK Medicines and Healthcare products Regulatory Agency (MHRA)

MHRA begins rolling review of Moderna’s mRNA vaccine against COVID-19.¹

Supply agreement
November 2020

Supply agreement

Moderna announces supply agreement with UK Government for COVID-19 mRNA vaccine if approved for use.²

UK MHRA approval
January 2021

UK MHRA approval

MHRA authorises the use of Moderna’s mRNA vaccine against COVID-19.³

COVAX
November 2021

COVAX

Moderna announces European Union and European Economic Area Countries to donate more than 70 million doses of Moderna COVID-19 Vaccine to COVAX in 2021 to help end COVID-19 pandemic in low income countries.⁴

Supply agreement 2021
December 2021

Supply agreement

Moderna and UK Government agree additional 60 million doses of mRNA COVID-19 vaccine for 2022-23.⁵

UK expansion
March 2022

UK expansion

New headquarters open in London, Victoria.

Bivalent booster
June 2022

Bivalent booster

Moderna announces Omicron-containing bivalent booster candidate mRNA-1273.214.⁶

¹United Kingdom Medicines and Healthcare products Regulatory Agency Authorizes Use of COVID-19 Vaccine Moderna. Businesswire 2021. Available at: https://www.businesswire.com/news/home/20210108005274/en/United-Kingdom-Medicines-and-Healthcare-products-Regulatory-Agency-Authorizes-Use-of-COVID-19-Vaccine-Moderna

²Moderna Announces Supply Agreement with United Kingdom Government to Supply mRNA Vaccine Against COVID-19 (mRNA-1273) if Approved for Use. Available at: Moderna Announces Supply Agreement with United Kingdom Government to Supply mRNA Vaccine Against COVID-19 (mRNA-1273) if Approved for Use | Business Wire

³United Kingdom Medicines and Healthcare products Regulatory Agency Authorizes Use of COVID-19 Vaccine Moderna, Available at:United Kingdom Medicines and Healthcare products Regulatory Agency Authorizes Use of COVID-19 Vaccine Moderna | Business Wire

⁴Moderna Announces European Union and European Economic Area Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to COVAX in 2021 to Help End COVID-19 Pandemic in Low Income Countries. Available at: Moderna Announces European Union and European Economic Area Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to COVAX in 2021 to Help End COVID-19 Pandemic in Low Income Countries | Business Wire

⁵Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna’s COVID-19 Vaccine in 2022 and 2023. Available at:Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna’s COVID-19 Vaccine in 2022 and 2023 | Business Wire

⁶Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron. Available at: Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron (modernatx.com)

UK-MRNA-2200004 July 2022 | © 2023 Moderna, Inc.